Short-term Abrocitinib Combined with Medicated Topical Therapy Provides Rapid Improvement in Pruritus in Elderly Patients with Moderate-to-severe Atopic Dermatitis: A Retrospective, Observational Real-world Study
DOI:
https://doi.org/10.2340/actadv.v105.44210Keywords:
atopic dermatitis, elderly patients, abrocitinib, pruritus, real-world dataAbstract
Abrocitinib, an oral small-molecule Janus kinase 1 (JAK1) inhibitor, is used for the treatment of -moderate-to-severe atopic dermatitis (AD). However, due to safety concerns, further clinical experience is warranted, especially for elderly patients with AD. The aim of this study was to assess the rapidity, effectiveness, and safety of short-term abrocitinib in combination with medicated topical therapy for managing -moderate-to-severe AD in elderly patients. A total of 57 elderly patients (≥65 years old) with moderate-to-severe AD who received oral abrocitinib at a dose of 100 mg/day, combined with topical medicated therapy for a minimum of 2 weeks, were included in the analysis. Results indicated that 91.23% of patients achieved the PP-NRS response at Week 2, and itching remained well controlled at Week 12. Additionally, 47.37% of patients achieved EASI-50, and 14.04% reached EASI-75 by Week 2. Notably, none of the 57 patients experienced any adverse events during the 12-week follow-up period. A shorter duration of AD was associated with better efficacy. Short-term abrocitinib in combination with medicated topical therapy may represent a new treatment approach in clinical practice for elderly AD patients, offering a rapid-onset and convenient treatment option to alleviate itching, achieve treatment goals, and manage medication risks simultaneously.
Downloads
References
Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2021; 157: 1047–1055. DOI: https://doi.org/10.1001/jamadermatol.2021.3023
Newton L, DeLozier AM, Griffiths PC, Hill JN, Hudgens S, -Symonds T, et al. Exploring content and psychometric validity of newly developed assessment tools for itch and skin pain in atopic dermatitis. J Patient Rep Outcomes 2019; 3: 42. DOI: https://doi.org/10.1186/s41687-019-0128-z
Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, -Fonacier L, Grayson MH, et al. Pain is a common and burdensome symptom of atopic dermatitis in United States adults. J Allergy Clin Immunol Pract 2019; 7: 2699–2706.e7. DOI: https://doi.org/10.1016/j.jaip.2019.05.055
Darlenski R, Kazandjieva J, Hristakieva E, Fluhr JW. Atopic -dermatitis as a systemic disease. Clin Dermatol 2014; 32: 409–413. DOI: https://doi.org/10.1016/j.clindermatol.2013.11.007
Ungar B, Garcet S, Gonzalez J, Dhingra N, Correa da Rosa J, Shemer A, et al. An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. J Invest Dermatol 2017; 137: 603–613. DOI: https://doi.org/10.1016/j.jid.2016.09.037
Kolb L, Ferrer-Bruker SJ. Atopic dermatitis. 2023 Aug 8. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing, 2025.
Takeuchi S, Esaki H, Furue M. Epidemiology of atopic dermatitis in Japan. J Dermatol 2014; 41: 200–204. DOI: https://doi.org/10.1111/1346-8138.12331
Choi WJ, Ko JY, Kim JW, Lee KH, Park CW, Kim KH, et al. Prevalence and risk factors for atopic dermatitis: a cross-sectional study of 6,453 Korean preschool children. Acta Derm Venereol 2012; 92: 467–471. DOI: https://doi.org/10.2340/00015555-1252
Tanei R. Atopic dermatitis in the elderly. Inflamm Allergy Drug Targets 2009; 8: 398–404. DOI: https://doi.org/10.2174/1871528110908050398
Tanei R, Katsuoka K. Clinical analyses of atopic dermatitis in the aged. J Dermatol 2008; 35: 562–569. DOI: https://doi.org/10.1111/j.1346-8138.2008.00524.x
Bocheva GS, Slominski RM, Slominski AT. Immunological aspects of skin aging in atopic dermatitis. Int J Mol Sci 2021; 22: 5729. DOI: https://doi.org/10.3390/ijms22115729
Nettis E, Ortoncelli M, Pellacani G, Foti C, Di Leo E, Patruno C, et al. A multicenter study on the prevalence of clinical patterns and clinical phenotypes in adult atopic dermatitis. J Investig Allergol Clin Immunol 2020; 30: 448–450. DOI: https://doi.org/10.18176/jiaci.0519
Bieber T, D’Erme AM, Akdis CA, Traidl-Hoffmann C, Lauener R, Schäppi G, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go? J Allergy Clin Immunol 2017; 139: S58–S64. DOI: https://doi.org/10.1016/j.jaci.2017.01.008
Williamson S, Merritt J, De Benedetto A. Atopic dermatitis in the elderly: a review of clinical and pathophysiological hallmarks. Br J Dermatol 2020; 182: 47–54. DOI: https://doi.org/10.1111/bjd.17896
Tanei R. Clinical characteristics, treatments, and prognosis of atopic eczema in the elderly. J Clin Med 2015; 4: 979–997. DOI: https://doi.org/10.3390/jcm4050979
Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, et al. Oral difelikefalin reduces moderate-to-severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis. J Allergy Clin Immunol 2023; 152: 916–926. DOI: https://doi.org/10.1016/j.jaci.2023.06.023
Kim RW, Lam M, Abuabara K, Simpson EL, Drucker AM. Targeted systemic therapies for adults with atopic -dermatitis: selecting from biologics and JAK inhibitors. Am J Clin Dermatol 2024; 25: 179–193. DOI: https://doi.org/10.1007/s40257-023-00837-w
Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 2020; 396: 255–266. DOI: https://doi.org/10.1016/S0140-6736(20)30732-7
Hagino T, Saeki H, Fujimoto E, Kanda N. Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol 2023; 50: 869–879. DOI: https://doi.org/10.1111/1346-8138.16763
Hagino T, Hamada R, Yoshida M, Fujimoto E, Saeki H, Kanda N. Effectiveness and safety of upadacitinib in combination with topical corticosteroids in adolescent patients with moderate-to-severe atopic dermatitis. Clin Cosmet Investig Dermatol 2023; 16: 3201–3212. DOI: https://doi.org/10.2147/CCID.S439053
Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol 2022; 86: 104–112. DOI: https://doi.org/10.1016/j.jaad.2021.05.075
Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, -Guttman-Yassky E, Hoffmeister KM, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol 2021; 22: 693–707. DOI: https://doi.org/10.1007/s40257-021-00618-3
Tanei R. Atopic dermatitis in older adults: a review of treatment options. Drugs Aging 2020; 37: 149–160. DOI: https://doi.org/10.1007/s40266-020-00750-5
De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol 2021; 101: adv00402. DOI: https://doi.org/10.2340/00015555-3751
Grine L, de la Brassinne M, Ghislain PD, Hillary T, Lambert J, Segaert S, et al. A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis management. J Eur Acad Dermatol Venereol 2020; 34: 676–684. DOI: https://doi.org/10.1111/jdv.16104
Werfel T, Heratizadeh A, Aberer W, Ahrens F, Augustin M, Biedermann T, et al. Update “Systemic treatment of atopic dermatitis” of the S2k-guideline on atopic dermatitis. J Dtsch Dermatol Ges 2021; 19: 151–168. DOI: https://doi.org/10.1111/ddg.14371
Farmer WS, Marathe KS. Atopic dermatitis: managing the itch. Adv Exp Med Biol 2024; 1447: 191–207. DOI: https://doi.org/10.1007/978-3-031-54513-9_16
Feldman SR, Guerin A, Gauthier-Loiselle M, Claxton AJ, Hazra NC, Meng Y, et al. Patient preferences for treatment attributes in moderate-to-severe atopic dermatitis: a discrete choice experiment. J Dermatolog Treat 2024; 35: 2345739. DOI: https://doi.org/10.1080/09546634.2024.2345739
Silverberg JI, Gooderham M, Katoh N, Aoki V, Pink AE, -Binamer Y, et al. Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol 2024; 38: 2139–2148. DOI: https://doi.org/10.1111/jdv.20229
Lugović-Mihić L, Barac E, Tomašević R, Parać E, Zanze L, -Ljevar A, et al. Atopic dermatitis-related problems in daily life, goals of therapy and deciding factors for systemic -therapy: a review. Pharmaceuticals (Basel) 2024; 17: 1455. DOI: https://doi.org/10.3390/ph17111455
Pierce EJ, Burge RT, Hirst AJ, Fox AM, Suokas AK, Yi Y. Economic burden of itch-related sleep loss in moderate-to-severe atopic dermatitis in the United Kingdom. Dermatol Ther (Heidelb) 2024; 14: 1103–1114. DOI: https://doi.org/10.1007/s13555-024-01153-9
Ebata T, Ohya Y, Ohshima Y, Andoh T, Tominaga M, Kataoka Y, et al. Recommendation for itch assessment from the atopic itch consensus meeting (AICOM). Arerugi 2024; 73: 171–179.
Drucker AM, Lam M, Flohr C, Thyssen JP, Kabashima K, Bissonnette R, et al. Systemic therapy for atopic dermatitis in older adults and adults with comorbidities: a scoping review and international eczema council survey. Dermatitis 2022; 33: 200–206. DOI: https://doi.org/10.1097/DER.0000000000000845
Teng Y, Zhong H, Yang X, Tao X, Fan Y. Current and emerging therapies for atopic dermatitis in the elderly. Clin Interv Aging 2023; 18: 1641–1652. DOI: https://doi.org/10.2147/CIA.S426044
Daniele S, Bunick C. JAK Inhibitor safety compared to traditional systemic immunosuppressive therapies. J Drugs Dermatol 2022; 21: 1298–1303. DOI: https://doi.org/10.36849/JDD.7187
Thyssen JP, Bewley A, Ständer S, Castro C, Misery L, Kim BS, et al. Abrocitinib provides rapid and sustained improvement in skin pain and is associated with improved quality of life outcomes in adult and adolescent patients with moderate-to-severe atopic dermatitis. Dermatology 2024; 240: 243–253. DOI: https://doi.org/10.1159/000535285
Eichenfield LF, Flohr C, Sidbury R, Siegfried E, Szalai Z, Galus R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol 2021; 157: 1165–1173. DOI: https://doi.org/10.1001/jamadermatol.2021.2830
Freitas E, Torres T. New molecules for atopic dermatitis treatment beyond biological therapy. Curr Opin Allergy Clin Immunol 2023; 23: 210–215. DOI: https://doi.org/10.1097/ACI.0000000000000910
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Yajie Yu, Yanqing Chen, Yuping Zhang, Mukai Chen, Yongzhi Han, Xinsheng Chen, Lei Ling, Xueling Tan, Junping Zhao, Rongzhi Liao, Jiajun He, Danyi Huang, Juan Luo, Chen Li, Han Ma
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
